Morbidity and Mortality Weekly Report: MMWRU.S. Department of Health, Education, and Welfare, Public Health Service, Center for Disease Control, 2008 |
From inside the book
Results 11-15 of 62
Page 399
... received ≥3 doses , 21,395 ( 95.0 % ) of 22,526 first doses at IIS sentinel sites and 25,629 ( 98.6 % ) of 26,005 ... receiving > 3 doses Doses administered First doses administered First doses administered at age 6-12 wks ( % of first ...
... received ≥3 doses , 21,395 ( 95.0 % ) of 22,526 first doses at IIS sentinel sites and 25,629 ( 98.6 % ) of 26,005 ... receiving > 3 doses Doses administered First doses administered First doses administered at age 6-12 wks ( % of first ...
Page 400
... receiving rotavirus vaccine during routine well - child visits at ages 4 and 6 months . To explore these hypotheses , analysis of IIS sentinel site and VSD data was restricted to infants who received > 3 doses ( i.e. , infants who were ...
... receiving rotavirus vaccine during routine well - child visits at ages 4 and 6 months . To explore these hypotheses , analysis of IIS sentinel site and VSD data was restricted to infants who received > 3 doses ( i.e. , infants who were ...
Page 402
... received a needlestick in a finger . The laboratory worker continued with the experiments , which involved two recombinant VACVs , and did not change gloves or wash hands until finished . The typical challenge dose for this set of ...
... received a needlestick in a finger . The laboratory worker continued with the experiments , which involved two recombinant VACVs , and did not change gloves or wash hands until finished . The typical challenge dose for this set of ...
Page 403
... receiving a carefully measured ( rather than ndetermined ) dose of a well - characterized vaccine formu- tion , which ... received prompt postexposure vacci- nation the day of the laboratory incident ; this might have contributed to ...
... receiving a carefully measured ( rather than ndetermined ) dose of a well - characterized vaccine formu- tion , which ... received prompt postexposure vacci- nation the day of the laboratory incident ; this might have contributed to ...
Page 435
... received Food and Drug Administration approval in February 2004 to manufacture and market cefixime . Lupin has been manu- facturing and marketing cefixime oral suspension ( 100 mg / 5 mL ) since February 2004 and cefixime oral ...
... received Food and Drug Administration approval in February 2004 to manufacture and market cefixime . Lupin has been manu- facturing and marketing cefixime oral suspension ( 100 mg / 5 mL ) since February 2004 and cefixime oral ...
Other editions - View all
Common terms and phrases
2008 are provisional ACIP American Samoa Anaplasma phagocytophilum area Current week Atlantic available in Table breastfeeding California Carolina children aged clinical Commonwealth of Northern Contains data reported Cumulative year-to-date counts Current 52 weeks Current week 52 Dakota data for reporting deaths Department of Health Disease Surveillance System Electronic Disease Surveillance Health and Human health-care Hepatitis Hispanic HIV/AIDS Human Services Incidence data infants infection influenza season influenza vaccine laboratory Legionellosis measles Median meningococcal disease MMWR Series National Center National Electronic Disease North Dakota Northern Mariana Islands notifiable diseases OOOOO oral fluid outbreak patients pertussis Previous 52 weeks public health Q fever Reporting area reporting years 2007 rotavirus selected notifiable diseases serogroup serotype Smoke-free Surveillance System NEDSS testing U.S. Virgin Islands United University Library UNIVERSITY UNIVERSITY OF CALIFORNIA/RIVERSIDE viral virus viruses week 52 weeks week Med Max West Nile virus workers York City York Upstate ZZZZ